英夫利昔单抗治疗炎症性肠病的疗效及影响因素分析  

Analysis of curative effect and influence factors of infliximab in the treatment of inflammatory bowel disease

作　　者：聂胜利[1] 吴军辉[1] 张庆芳[1] 

机构地区：[1]广东省人民医院消化内科,510060

出　　处：《中国实用医药》2015年第5期13-14,共2页China Practical Medicine

摘　　要：目的探讨英夫利昔单抗在治疗炎症性肠病中的疗效及影响因素。方法炎症性肠病患者62例随机分为对照组和观察组,各31例,其中对照组给予美沙拉秦进行治疗,观察组采用英夫利昔单抗进行治疗,比较两组患者治疗有效率、黏膜愈合率以及复发等情况,同时对影响患者的发病因素进行归纳分析。结果对比结果显示,对照组中治疗有效率为64.5%(20/31),黏膜愈合率38.7%(12/31),缓解率为29.0%(9/31);观察组中治疗有效率为87.1%(27/31),黏膜愈合率58.1%(18/31),缓解率为9.7%(3/31),两组对比差异有统计学意义(P<0.05)。结论在炎症性肠病临床治疗中,采用英夫利昔单抗的方法进行治疗具有较好的疗效,可有效改善患者临床症状,加快胃肠黏膜愈合,值得在临床上进行推广和应用。Objective To explore curative effect and influence factors of infliximab in the treatment of inflammatory bowel disease. Methods A total of 62 patients with inflammatory bowel disease were randomly divided into control group and observation group, with 31 cases in each group. The control group received mesalazine for treatment, and the observation group was treated by infliximab. The treatment effective rate, mucous membrane healing rate, and relapse of the two groups were compared. An inductive analysis was made on the influence factors of pathogenesis. Results The comparison showed that the treatment effective rate of the control group was 64.5%（20/31）, the mucous membrane healing rate was 38.7%（12/31）, and the remission rate was 29.0%（9/31）. The observation group had the treatment effective rate as 87.1%（27/31）, the mucous membrane healing rate as 58.1%（18/31）, and the remission rate as 9.7%（3/31）. The difference between the two groups had statistical significance（P〈0.05）. Conclusion The application of infliximab has good curative effect in clinical treatment for inflammatory bowel disease, and it can effectively improve patients＇ clinical symptoms and accelerate rehabilitation of gastrointestinal mucosa. This method is worth promotion and application in clinic.

关 键 词：英夫利昔单抗 炎症性肠病 应用疗效 影响因素 

分 类 号：R574[医药卫生—消化系统]